In a strategic move to bolster its oncology portfolio, AstraZeneca announced its acquisition of Fusion Pharmaceuticals Inc. ( NASDAQ:FUSN ) for a staggering $2 billion in cash. This bold step underscores AstraZeneca's commitment to pioneering next-generation cancer therapies.
Fusion Pharma ( NASDAQ:FUSN ), a clinical-stage biopharmaceutical company, has been...